The Federal Office for Safety in Health Care has been informed by the Italian authority that WNV NAT testing will now be carried out in the province of Padova (Veneto Region) in addition to the regions already announced.

CSL Behring as distributor of the product Helixate®NexGen has, in coordination with the marketing authorization holder Bayer Pharma AG, informed its supplied customers by letter dated August 8, 2016, that above mentioned batches of Helixate®NexGen are recalled. Stability data for these batches indicated a faster than usual decline in potency.…

The Federal Office for Public Health Safety has been informed by the Italian authority that WNV NAT testing will now be carried out in the province of Forli-Cesena (Emilia-Romagna Region) in addition to the regions already announced.

The Federal Office for Public Health Safety has been informed by the Italian authority that WNV NAT testing will now be carried out in the provinces of Torino (Piedmont Region), Monza-Brianza (Lombardia Region), and Veneto (Veneto Region) in addition to the regions already announced.

The marketing authorization holder has informed its supplied customers in a letter dated August 4, 2016, that after the application of "Nutriflex Lipid special Emulsion for Infusion " of the batch 160338052 individual cases of fever and chills have occurred. Since it cannot be ruled out at this time that the reported adverse reactions are related…

The Federal Office for Public Health Safety has been informed by the Italian authority that WNV NAT testing will now be carried out in the provinces of Parma (Emilia-Romagna Region) and Cremona (Lombardia Region) in addition to the regions already announced.

The distribution company "Chevita Tierarzneimittel Ges.m.b.H." has informed its supplied customers with 05.07.2016 that in the course of stability tests a reduced content of active ingredient was found and therefore the affected packages of this drug for racing pigeons will be recalled.

The Federal Office for Public Health Safety has been informed by the Italian authority that the first human WNV (neuro-invasive disease) infection has been recorded in the province of Bologna (Emilia-Romagna Region).

Since the market launch of "Velactis" in March 2016, serious side effects have been reported. the Scientific Committee for Medicinal Products for Veterinary Use of the European Medicines Veterinary Use) of the European Medicines Agency (EMA) has decided to notify the European Commission of a a suspension of the marketing authorization and a…

The marketing authorization holder has informed its supplied customers that a recall of all batches of "Velactis" on the market will be carried out, as serious side effects have been reported since market launch. The Scientific Committee for Medicinal Products for Veterinary Use of the European Medicines Agency (EMA) has therefore decided to…